Follow us on Twitter
twitter icon@FreshPatents


Expression Vector patents

      

This page is updated frequently with new Expression Vector-related patent applications.




 Methods for diagnosing diseases associated with human signal peptide-containing molecules patent thumbnailnew patent Methods for diagnosing diseases associated with human signal peptide-containing molecules
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


 Fusion protein for inducing pluripotent stem cells and application method thereof patent thumbnailnew patent Fusion protein for inducing pluripotent stem cells and application method thereof
Provided is a protein coded by a gene related to cell totipotency and a transcriptional activation domain of a mammalian yap protein or a fusion protein of a segment with a transcriptional control activity, a coding nucleotide sequence, an expression vector and a composition thereof, as well as a method for inducing the pluripotent stem cells by using the fusion protein.. .
Emory University School Of Medicine


 Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein patent thumbnailnew patent Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein
A tgal-3bp-fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and t-cell functions by using the same are disclosed herein. The tgal-3bp-fc fusion protein comprises: a truncated gal-3 binding protein with domain 4, and at least an fc fragment of an immunoglobulin g.
Show-chwan Memorial Hospital


 Insecticidal proteins from plants and methods for their use patent thumbnailnew patent Insecticidal proteins from plants and methods for their use
Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
E. I. Du Pont De Nemours And Company


 T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines patent thumbnailnew patent T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
The present invention concerns methods and compositions for treatment of hiv infection using a t20 expression vector, such as that shown in seq id no:1 or seq id no:3. The t20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to hiv, localized transfection in vivo in a gene therapy approach to provide longer term delivery of t20, or in vitro production of t20 peptide.
Immunomedics, Inc.


 Nov mini-promoters patent thumbnailNov mini-promoters
Isolated polynucleotides comprising a nov mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, including, but not limited to, reporter genes, genes encoding a polypeptide of interest, and regulatory rna sequences such as mirna, sirna, and anti-sense rna.
The University Of British Columbia


 Sorghum-derived transcription regulatory elements predominantly active in root hair cells and uses thereof patent thumbnailSorghum-derived transcription regulatory elements predominantly active in root hair cells and uses thereof
Transcription regulatory elements, namely promoter and terminator sequences, obtained from sorghum bicolor that drive rna transcription predominately in root hair cells are described, as well as cassettes, expression vectors, and genetically modified plants containing these transcription regulatory elements. The genetically modified plants can be gymnosperms, dicots, or monocots.
The United States Of America, As Represented By The Secretary Of Agriculture


 Novel oligo-linker-mediated dna assembly method and applications thereof patent thumbnailNovel oligo-linker-mediated dna assembly method and applications thereof
A method for generating a library of expression vectors comprising a plurality of donor sequences and a plurality of oligo-linker nucleic acids, termed oligonucleotide linker-mediated dna assembly (olma), is described. Also described are applications of the olma method, including the simultaneous tuning of several factors in metabolic and biological pathways, and the combinatorial high throughput optimization of metabolic and biological pathways..
Nanjing Jinsirui Science & Technology Biology Corporation


 Trispecific binding proteins and methods of use patent thumbnailTrispecific binding proteins and methods of use
Provided herein are trispecific antigen-binding proteins comprising a domain binding to cd3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins.
Harpoon Therapeutics, Inc.


 B7-related nucleic acids and polypeptides useful for immunomodulation patent thumbnailB7-related nucleic acids and polypeptides useful for immunomodulation
The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3.
Bristol-myers Sqibb Company


Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors

Polypeptides and proteins that specifically bind to and immunologically recognize ny-br-1 are disclosed. Chimeric antigen receptors (cars), anti-ny-br-1 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer

Disclosed are next-generation multi-mutated capsid protein-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols.
University Of Florida Research Foundation, Inc.

Yield improvement in plants

Polynucleotides and polypeptides incorporated into expression vectors are introduced into plants and were ectopically expressed. These polypeptides may confer at least one regulatory activity and increased yield, increased light use efficiency, increased photosynthetic capacity, increased photosynthetic rate, increased photosynthetic resource use efficiency, greater vigor, and/or greater biomass as compared to a control plant..
Koch Biological Solutions, Llc

Dna vector production system

A vector production system is provided. The system comprises recombinant cells designed to encode at least a first recombinase under the control of an inducible promoter and the cells include an expression vector encoding a nucleic acid of interest within the regulatory elements of the expression vector which are flanked on either side by a target sequence for at least the first recombinase.

Systems and methods for the secretion of recombinant proteins in gram negative bacteria

Disclosed herein are systems and methods for producing recombinant proteins utilizing mutant e. Coli strains containing expression vectors carrying nucleic acids encoding the proteins, and secretory signal sequences to direct the secretion of the proteins to the culture medium.
Cornell University

Improved enzyme variants

The invention relates to a variant polypeptide having lactase activity. The invention also relates to a nucleic acid sequence encoding such a variant polypeptide, to a nucleic acid construct comprising said nucleic acid sequence, to a recombinant expression vector comprising said nucleic acid construct and to a recombinant host cell comprising said expression vector.
Dsm Ip Assets B.v.

Neutralizing gp41 antibodies and their use

Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

The use of sdf-1 to mitigate scar formation

The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of sdf-1 in, or proximate to, the wound. As described herein sdf-1 protein or an sdf-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of sdf-1 protein or an sdf-1 expression vector..
The Cleveland Clinc Foundation

Novel human genes relating to respiratory diseases and obesity

This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein..
Oscient Pharmaceuticals Corporation

Method for directed dna evolution using combinatorial dna libraries

The present invention provides a method of rapid directed dna evolution based on single-stranded combinatorial dna mutant library. The single- and double-stranded mutant library are constructed either separately or simultaneously using editing primers that contain mutated nucleotides and are targeted to different regions of the parent dna sequence.
Jiangnan University

Randomized humanized antibody libraries engineered with sequence and insert diversity

A phage display library is formed by a plurality of recombinant phages; each of the plurality of recombinant phages comprising an m13-derived expression vector; the m13-derived expression vector comprising a polynucleotide sequence encoding a randomized peptide, wherein the randomized peptide is a variable region of a human igg1 heavy chain; the randomized peptide is expressed in absence of an immunoglobulin light chain protein on an outer surface of a recombinant phage of the phage display antibody library; and a protein product expressed by a recombinant phage of the phage display antibody library fuses with a human immunoglobulin constant region to form a full human igg1 heavy chain molecule. The phage display library can be utilized to identify candidate antibodies that can bind to receptor axl and other receptors..
Helio Genetics Inc.

Ultrasound-assisted gene transfer for treatment of xerostomia

Methods and compositions useful for gene transfer into a salivary gland are provided. In certain aspects, methods and compositions useful in the treatment of hyposalivation and/or xerostomia are provided.
Allegheny-singer Research Institute

Anti-vasa antibodies, and methods of production and use thereof

Anti-vasa antibodies (mabs), particularly humanized mabs that specifically bind to vasa with high affinity, are disclosed. The amino acid sequences of the cdrs of the light chains and the heavy chains, as well as consensus sequences for these cdrs, of these anti-vasa mabs are provided.
Ovascience, Inc.

Anti-kit antibodies and uses thereof

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human kit antigen comprising the fourth and/or fifth extracellular ig-like domains (that is, d4 and/or d5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit kit activity, such as ligand-induced receptor phosphorylation.
Kolltan Pharmaceuticals, Inc.

Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same

The invention provides a chimeric antigen receptor (car) comprising an antigen binding domain specific for tslpr, a transmembrane domain, and an intracellular t cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

Polynucleotide, polypeptide with immunosuppressive activity, expression cassette, expression vector, host cell, pharmaceutical composition, methods for producing a polypeptide with immunosuppressive activity and for preventing or treating conditions that require immunosuppression, and use of a polypeptide

This invention refers to polynucleotides and non-hemorrhagic and non-immunogenic polypeptides of selective immunosuppressive activity on production of antibodies to antigens of different natures. The polypeptides described herein are useful for preparing pharmaceutical compositions for prevention or treatment of conditions that require immunosuppression, preferably, inflammatory, autoimmune, allergic and infectious diseases and rejection to transplanted organs..
FundaÇÃo Butantan

Expression vector having improved ability to express gene

The present invention relates to an expression vector having an improved ability to express a gene, cells transformed by the expression vector, and a method for mass-producing a target protein by using the cells. The expression vector according to the present invention shows a more excellent ability to express a gene than a typical animal cell expression vector, and thus, protein expression of a heterogeneous gene can be significantly increased..
Mogam Biotechnology Institute

Coexpression of cas9 and trex2 for targeted mutagenesis

A composition used in targeted mutagenesis is provided, which includes a first expression cassette comprising a nucleotide sequence which encodes a cas9 endonuclease; a second expression cassette comprising a nucleotide sequence which encodes a guide rna sequence, wherein the guide rna sequence is complementary to a target genome nucleotide sequence in a cell; and a third expression cassette comprising a nucleotide sequence which encodes a trex2 exonuclease (trex2) gene. The first, second, and third expression cassettes may be a part or a portion of one or more expression vectors..
City Of Hope

Potent and selective inhibitors of nav1.3 and nav1.7

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of nav1.7 and/or nav1.3.
Amgen Inc.

Dna vaccine containing specific epitope of apolipoprotein (a)

The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric hepatitis b virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis b virus core antigen polypeptide.. .
Angesmg, Inc.

Nucleic acid molecules for increased protein production

The present invention relates to the improved production of proteins, preferably enzymes such as lipases. In particular, the invention relates to a mutated signal peptide and nucleotide sequence encoding said signal peptide that results in an increased protein secretion.

Engineered glycoproteins and uses thereof

The present invention provides for novel glycoproteins comprising therapeutically useful polypeptides, or fragments or variants thereof, conjugated to glycosylated amino acid block copolymer polypeptides. These novel glycoproteins possess improved half-life properties as compared to the unmodified therapeutically useful polypeptide.
Aequus Biopharma, Inc.

Vectors and methods for enhancing recombinant protein expression in plants

Expression vectors and methods of their use for enhancing the production of recombinant proteins in plants or plant cells are described. Production can be further enhanced upon co-expression of the p19 suppressor of gene-silencing from tomato bushy stunt virus.
University Of Guelph

Antibodies anti matriptase for the treatment of cancer

The invention provides antibodies which bind to the extracellular domain of the tyrosine-protein kinase transmembrane receptor matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd

Bicistronic expression vector for antibody expression and producing antibody using same

The present invention relates to a bicistronic expression vector for antibody expression, an animal cell transfected with the expression vector, and a method for producing an antibody including culturing the animal cell, in which the expression vector includes a first expression cassette including ‘promoter-utr-intron-antibody light chain gene-polya’ and a second expression cassette including ‘promoter-utr-intron-antibody heavy chain gene-internal ribosome entry site (ires)-amplification gene-polya’. An expression vector capable of expressing a desired antibody with high efficiency can be constructed using the bicistronic expression vector including an intron for antibody expression according to the present invention, and the expression vector can produce the antibody by culturing the transfected animal cell with stability and high efficiency..
Prestige Biopharma Pte. Ltd.

Phi-4 polypeptides and methods for their use

Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
Pioneer Hi-bred Interantional, Inc.

Alk antibodies, conjugates, and chimeric antigen receptors, and their use

Chimeric antigen receptors that specifically bind to anaplastic lymphoma kinase are disclosed. Nucleic acids, recombinant expression vectors, host cells, antibodies, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed.
The United States Of America, As Represented By The Secretary Department Of Health & Human Service

Human leucine zipper/trail recombinant polypeptides

Disclosed are recombinant polypeptides that include human trail sequences as well as human leucine zipper motifs as well as polynucleotides that encode the recombinant polypeptides, expression vectors that comprise the polynucleotides, pharmaceutical compositions comprising the polypeptides, and methods of using the pharmaceutical compositions for the treatment of cancer. Further disclosed are trail sequences with stabilizing mutations and methods of expressing the disclosed polypeptides in e.
Sanford Burnham Prebys Medical Discovery Institute

Ama-1 epitopes, antibodies, compositions, and methods of making and using the same

Disclosed are ama-1 immunogenic peptides and epitopes, nucleotide sequences encoding the peptides and epitopes, compositions, and vaccines including the peptides and/or epitopes. Antibodies that specifically bind to ama-1 and the ama-1 epitopes and immunogenic peptides disclosed herein are also provided.
The Goverment Of The United States, As Represented By The Secretary Of The Army

Anti-ssx-2 t cell receptors and related materials and methods of use

The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for synovial sarcoma x breakpoint (ssx)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Fungal resistant plants expressing casar

The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of a casar protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh

Resource use efficiency improvement in plants

Polynucleotides and polypeptides incorporated into expression vectors are introduced into plants and were ectopically expressed. These polypeptides may confer at least one regulatory activity and increased yield, increased resource use efficiency, increased water use efficiency, increased light use efficiency, increased photosynthetic capacity, increased photosynthetic rate, increased photosynthetic resource use efficiency, greater vigor, and/or greater biomass as compared to a control plant..
Mendel Biotechnology, Inc.

Compositions and methods containing a constitutive promoter to modify the expression of genes of interest in plants

The present invention relates to a new promoter of the expression of genes in plants. More specifically, the invention relates to regulatory sequences of polynucleotides that are isolated from soy plants and can initiate and activate polynucleotide transcription, and to the use of these regulatory sequences to modify the transcription of endogenous and/or heterologous polynucleotides and to produce polypeptides.
Empresa Brasileira De Pesquisa Agropecuária - Embrapa

Anti-pd-1 antibody and use thereof

This invention provides antibodies or functional fragments thereof that bind to pd-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention.
Junmeng Biosciences Co., Ltd

Vectors and host cells comprising a modified sv40 promoter for protein expression

The present disclosure is directed to expression vectors, comprising a weakened sv40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells.. .
Abbvie Biotherapeutics Inc.

Novel adenovirus isolated from titi monkeys

Provided is a titi monkey adenovirus (tmadv) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-tmadv antibodies, vaccines, compositions, methods of detecting tmadv, methods for assaying for anti-tmadv compounds, and methods for treating or preventing a tmadv infection..
The Regents Of The University Of California

Compositions and methods for treating cardiovascular diseases using foxp3

The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter or a constitutive promoter linked to a gene encoding a therapeutic agent, such as a protein, microrna, sirna or other therapeutical molecule, e.g., other oligonucletide. The therapeutic agent may be, for example, interleukin 10 (il10), forkhead box p3 (foxp3), or a member of a transforming growth factor beta 1 (tgfβ1) signaling pathway, such as smad3..
Kiromic, Llc

Conjugated antibodies against ly75 for the treatment of cancer

The invention provides antibodies which bind to ly75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd

Alpha-amylase and alpha-amylase variants

The invention relates to a novel termamyl-like alpha-amylase, and termamyl-like alpha-amylases comprising mutations in two, three, four, five or six regions/positions. The variants have increased thermostability at acidic ph and/or at low ca2+ concentrations (relative to the parent).
Novozymes A/s

Cell expression system

An expression system for expressing a protein comprising: a eukaryotic host cell carrying a dihydrofolate reductase (dhfr) deficiency; and an expression vector, the expression vector encoding the human growth hormone gene; a expression vector, the expression vector comprising: a eukaryotic selectable marker including a minimal sv 40 early promoter driving expression of a sequence encoding dihydrofolate reductase for complementing the dhfr deficiency in the host cell; a prokaryotic selectable marker conveying ampicillin resistance to a prokaryotic host cell; a prokaryotic origin of replication; a plurality of multiple cloning sites (mcs); and at least one protein expression module comprising: a simian vacuolating virus 40 (sv40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit β-globin intron sequence being separable from a sv40 p a sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom.. .
Neuclone Biologics Pty Ltd

Novel ferulate esterase isolated from lactobaccillus fermentum

The cdna and amino acid sequences of a ferulate esterase obtained from lactobacillus fermentum nrrl b-1932 is determined. An expression vector for expression of the ferulate esterase gene is generated.
The United States Of America, As Represented By The Secretary Of Agriculture

Use of endostatin peptides for the treatment of fibrosis

C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Novel epitope for switching to th17 cell and use thereof

The present invention relates to a novel epitope to convert t cell to type 17 helper t (th17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (seq id no.
National Cancer Center



Expression Vector topics:
  • Expression Vector
  • Recombinant
  • Nucleic Acid
  • Antibodies
  • Polypeptide
  • Amino Acid
  • Amino Acid Sequence
  • Nucleic Acids
  • Polynucleotide
  • Nucleotide
  • Cytomegalovirus
  • Endothelial
  • Extracellular
  • Endothelial Cell
  • Epithelial


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.0817

    file did exist - file did put2806

    3 - 1 - 53